Arcturus Therapeutics Q1 Revenue Plummets 93% to $2.06M, Net Loss Widens
ARCT sits 23% above its 52-week low of $5.85.
Summary
Arcturus Therapeutics reported a significant deterioration in its financial performance for Q1 2026, with revenue plummeting 93% year-over-year to $2.06 million and net loss widening to $27 million, or $(0.95) per share. This continues the negative trend observed in fiscal year 2025, which saw a substantial revenue decline and increased cash burn. The company's revenue mix has shifted as its KOSTAIVE product moved from development to commercial phase, impacting deferred revenue amortization. Furthermore, ongoing issues with partner CSL Seqirus, including a $430 million write-down and arbitration over an EU marketing authorization milestone, continue to weigh on collaboration economics. These results indicate significant operational challenges and a worsening financial position, which will likely pressure the stock. Investors will be closely watching the progress of its clinical programs and the resolution of the CSL Seqirus dispute for future catalysts.
At the time of this announcement, ARCT was trading at $7.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $253M. The 52-week trading range was $5.85 to $24.17. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.